Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte and Fleury Announce Partnership to Make the Afirma® Gene Expression Classifier Available to Patients in Brazil
SOUTH SAN FRANCISCO , Calif. and SAO PAULO, Brazil , May 2, 2014 /PRNewswire/ --  Veracyte, Inc . (Nasdaq: VCYT) and Fleury Medicine and Health today announced a new partnership that will make Veracyte's Afirma Gene Expression Classifier (GEC) available to patients in Brazil , helping to reduce
View HTML
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss First Quarter 2014 Financial Results on May 8, 2014
SOUTH SAN FRANCISCO, Calif. , May 1, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) announced today that its first quarter 2014 financial results will be released after close of market on Thursday, May 8 , 2014.  Following the announcement, Veracyte's management will host a live conference
View HTML
Toggle Summary Veracyte, Inc. Announces Fourth Quarter and Full-Year 2013 Financial Results, Provides 2014 Financial Outlook
-- 88% Growth in Full-Year 2013 Revenue, 92% Growth in Year-Over-Year FNA Volume ---- Increased Coverage and Reimbursement for Afirma® Gene Expression Classifier ---- Conference Call Today at 5 p.m. ET --
View HTML
Toggle Summary Veracyte, Inc. Appoints Julie A. Brooks as Executive Vice President, General Counsel and Secretary; and Andy Thorson as Executive Vice President, Corporate Strategy and Business Development
SOUTH SAN FRANCISCO, Calif. , March 17, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A.
View HTML
Toggle Summary Veracyte, Inc. to Announce Fourth Quarter and Full-Year 2013 Financial Results and Host Conference Call on Tuesday, March 18, 2014
SOUTH SAN FRANCISCO, Calif. , March 11, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014 . Following the release, Veracyte will host a live conference call
View HTML
Toggle Summary Veracyte Updates Presentation Date and Time at the Cowen and Company 34th Annual Health Care Conference
-- Presentation and Webcast Scheduled for Tuesday, March 4, at 8 a.m. ET --
View HTML
Toggle Summary Veracyte to Present at Cowen and Company 34th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , president and chief executive officer, will present at the Cowen and Company 34 th Annual Health Care Conference on Wednesday, March 5, 2014 at 10 a.m.
View HTML
Toggle Summary Veracyte To Present At 2014 Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO , Feb. 5, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , president and chief executive officer, will present at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 11:30 a.m. ET in New York .
View HTML
Toggle Summary Veracyte Announces Cigna Coverage for the Afirma® Gene Expression Classifier
SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2013 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that Cigna, one of the nation's leading providers of health insurance, has issued a positive coverage policy for
View HTML
Toggle Summary Veracyte, Inc. Announces Third Quarter 2013 Financial Results
-- 3Q Revenue Reached $5.6 Million, Increasing 74% Compared to Prior Year ---- Coverage and Reimbursement Continue to Expand for Afirma® Gene Expression Classifier (GEC) ---- Company Successfully Completed Initial Public Offering on November 4 ---- Conference Call Today at 5 p.m. ET --
View HTML